|
|
|
| Comparison of the Effect of Conbercept or Rapunzumab Combined with Laser in the Treatment of BRVO with Macular Edema |
| SONG Qingxue, MA He |
| Liaoyang Central Hospital, Liaoning Liaoyang 111000, China |
|
|
|
|
Abstract Objective: To investigate the effect of conbercept or laser in the treatment of branch retinal vein occlusion (BRVO) with macular edema, and to analyze the relationship between visual acuity and the central macular thickness (CMT) and the outer nuclear layer thickness (ONLT). Methods: 89 cases (89 eyes) of BRVO patients with macular edema treated in our hospital from March 2016 to June 2019 were randomly divided into the observation group (45 cases and 45 eyes) and the control group (44 cases and 44 eyes). The observation group was treated with conbercept and fundus laser, and the control group was treated with leizhumab and fundus laser. BCVA, CMT, ONLT and macular leakage were observed. the relationship between BCVA, CMT andONLT were analyzed. Results: There was significant difference in BCVA at different time and time interaction between groups (P<0.05), but no significant difference between groups (P>0.05). CMT and ONLT had significant difference in different time (P<0.05), but no significant difference in the interaction between groups and time (P>0.05). The CMT and ONLT of the two groups decreased with the time after treatment, and BCVA increased. The CMT and ONLT of the two groups were lower than before treatment at different time points after treatment, and BCVA was higher than before treatment (P>0.05). The BCVA of the observation group was higher than that of the control group at 1, 2 and 3 months after treatment, the CMT of the observation group was lower than that of the control group at 3 months after treatment, and the ONLT of the observation group was lower than that of the control group at 2 and 3 months after treatment (P<0.05). Conclusion: The effect of conbercept combined with fundus laser in BRVO patients with macular edema is better than that of leizhumab combined with fundus laser. It has high security.
|
|
|
|
|
|
[1] 高鸽,姜媛,孙红芬,等.超广角荧光素眼底血管造影在视网膜分支静脉阻塞诊治中的应用[J].眼科新进展,2018,38(7):677~679.
[2] 王林妮,于荣国,杨锦,等.视网膜分支静脉阻塞患眼浅层与深层毛细血管层黄斑区微血管形态改变的差异[J].中华眼底病杂志,2018,34(1):13~16.
[3] 郑小燕,潘晓霞,靳翠.雷珠单抗联合眼底激光治疗视网膜分支静脉阻塞继发黄斑水肿的价值研究[J].中国基层医药,2019,26(17):2114~2118.
[4] 徐冲,冯超,吴建华.OCTA在雷珠单克隆抗体治疗视网膜分支静脉阻塞合并黄斑水肿视力预测中的应用分析[J].临床眼科杂志,2018,26(5):390~393.
[5] 蒋博,刘畅,张中宇,等.首次抗VEGF早期应答对视网膜分支静脉阻塞继发黄斑水肿治疗的预测作用[J].中华眼视光学与视觉科学杂志,2019,21(5):362~369.
[6] 刘雪莲,牟洁,颜学梅,等.雷珠单抗联合激光治疗视网膜分支静脉阻塞所致黄斑水肿的临床研究[J].河北医学,2015,21(12):2006~2008.
[7] 朱媛,杜善双,田芳.康柏西普玻璃体腔注射治疗湿性老年性黄斑变性临床观察[J].陕西医学杂志,2017,46(2):262~263.
[8] 张旭,刘庆淮,王秀英,等.玻璃体腔注射ozurdex或康柏西普治疗黄斑水肿的临床疗效[J].江苏医药,2019,45(6):576~578.
[9] 纪敏,杨曙涛.康柏西普联合激光治疗视网膜静脉血管阻塞并发黄斑囊样水肿疗效观察[J].中国药业,2019,28(3):68~70. |
|
|
|
2020, Vol. 26 
